ClinicalTrials.gg
CompletedNCT02912156Updated Sep 23, 2016

Pharmacokinetics of Two Different Formulation of Voriconazole

A Phase 4 interventional study of Vaway FC Tablets 200mg (Voriconazole) and VFEND FC Tablets 200mg (Voriconazole) in Fungus Infection, sponsored by Yung Shin Pharm. Ind. Co., Ltd.. Completed. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-23.

Sponsored by Yung Shin Pharm. Ind. Co., Ltd. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing voriconazole in Mycoses — none open to participants now, none under way, none of them phase 3. Voriconazole · Mycoses.

Enrollment
9th of 17
29 · median 29
Started
2016
the only one that year
Phase 4
4 of 17
none open now
Registered
16th of 17
by date
Lead sponsor
1 of 17
Yung Shin Pharm. Ind. Co., Ltd.

Among the 17 studies testing voriconazole in Mycoses, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 4 in phase 4, and was the 16th registered.

Mycoses

260 studies on the registry are indexed under Mycoses; 37 are open to participants now.

Browse Mycoses studies →

Open to participants now

None of the 17 studies testing voriconazole in Mycoses is open now. The open studies under Mycoses, anywhere →

About voriconazole

Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Mycoses studies recruiting now, 13 (54%) set no upper age limit and 4 (17%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.

This study: 20 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing voriconazole in Mycoses as a file.
02

Study summary

A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Formulation of Voriconazole 200 mg Tablets in Healthy Adult Subjects.

03

Conditions studied

  • Fungus Infection

Browse trials for

Keywords

  • Pharmacokinetic
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult, aged between 20 to 45 years old.
  2. Physically and mentally healthy subjects as confirmed by an interview, medical history review, clinical examination, laboratory tests, chest x-ray and (ECG).

    • No finding in clinical examination and laboratory tests within two months (60 days) prior to administration of study medication;
    • Normal or clinically not significant at the discretion of the investigator chest X-ray and ECG results within six months (180 days) prior to administration of study medication.
  3. Body weight was above 50 kg for male and 45 kg for female.
  4. The should be between 18 and 27; body mass index equals [weight (kg)]/[height (m)]2.
  5. Laboratory determinations results were within normal range or considered not clinically significant by the investigator, including: Serum Glutamic Oxaloacetic Transaminase (, same as AST), Serum Glutamic Pyruvic Transaminase (SGPT, same as ALT), albumin, glucose, creatinine, uric acid, cholesterol, Triglycerides (TG), Gamma-Glutamyl-Transpeptidase (γ-GT), alkaline phosphatase, total , Blood Urea Nitrogen(BUN), surface antigen (HBsAg), Anti- virus (Anti-HCV) and Anti- (Anti-HIV) test.
  6. Hematology test results were within normal range or considered not clinically significant by the investigator, including: , hematocrit, White Blood Cell (WBC) count, Red Blood Cell (RBC) count, count and WBC count with differential.
  7. Urinalysis results were within normal range or considered not clinically significant by the investigator, including: glucose, protein, RBC, WBC, epith, casts and bacteria.
  8. Adequate methods must be used during two weeks prior and two weeks after to the administration of study medication.
  9. Female subject who was:

    • Using adequate contraception since last menstruation and no plan for conception during the study.
    • Non-lactating.
    • Had negative pregnancy test (urine) prior to the study.
  10. form signed.

Exclusion criteria

Exclusion Criteria:

  1. A history of drug or alcohol abuse within 24 weeks prior to the study.
  2. History of drug allergy, allergic constitution, asthma or retinal disease.
  3. Myopia worse than 6.0 diopters.
  4. A illness (such as hematological ) within the past 4 weeks
  5. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic, neurological, pulmonary or gastrointestinal disease within the past 4 weeks.
  6. Planned vaccination during the study.
  7. Participation of any clinical investigation during the last 60 days.
  8. Regular use of any medication during the last 4 weeks.
  9. Single use of any medication during the last 2 weeks.
  10. Blood donation of more than 250 mL within the past 12 weeks.
  11. Individuals were judged by the investigator to be undesirable as subjects.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Vaway FC Tablets

    Vaway FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing

    Drug: Vaway FC Tablets 200mg (Voriconazole)

  • Active comparator
    VFEND FC Tablets

    VFEND FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing

    Drug: VFEND FC Tablets 200mg (Voriconazole)

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration (AUC)

    Time frame: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr

  2. Peak Drug Concentration (Cmax)

    Time frame: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr

  3. Time to reach Cmax (Tmax)

    Time frame: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr

  4. Elimination half-life (T1/2)

    Time frame: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr

  5. Area under the (first) moment plasma concentration-time curve (AUMC)

    Time frame: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr

Secondary outcomes

  1. Adverse events

    Time frame: Within 8 weeks prior to the study, subjects were screened for their eligibility.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Jul 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2016
First posted
Sep 23, 2016
Start
Jun 2016
Primary completionActual
Jul 2016
CompletionActual
Aug 2016
Last update
Sep 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02912156
Lead sponsor
Yung Shin Pharm. Ind. Co., Ltd.
Responsible party
Sponsor
First posted
Sep 23, 2016
Start date
Jun 2016
Primary completion
Jul 2016
Completion
Aug 2016
Last update
Sep 23, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion